<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616013</url>
  </required_header>
  <id_info>
    <org_study_id>VER201-PH2-031</org_study_id>
    <nct_id>NCT05616013</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versanis Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versanis Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to&#xD;
      assess efficacy and safety in overweight or obese men and women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates if bimagrumab in addition to semaglutide is able to preserve/increase&#xD;
      muscle mass in the presence of weight and/or fat mass loss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2022</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The study is designed as a factorial of 3 semaglutide doses (none, 1.0 mg and 2.4 mg) and 3 bimagrumab doses (0, 10 and 30 mg/kg).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>In regards to bimagrumab and placebo-bimagrumab, the participants, Investigator and Sponsor will be blinded.&#xD;
Due to semaglutide being pre-filled, packaged and labeled by manufacturer, it is not possible to blind semaglutide.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in body weight at 48 weeks</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Percent change in total body weight will be measured from baseline to 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in WC (cm) at 48 weeks</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline at 48 weeks in body fat mass in kilograms (kg)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Body weight will be measured in kilograms (kg) to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at 48 weeks in body fat mass in kilograms (kg)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Body weight will be measured in kilograms (kg) to the nearest 0.1 kg and reported as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline at 48 weeks in visceral adipose tissue (VAT) or trunk fat mass by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at 48 weeks in visceral adipose tissue (VAT) or trunk fat mass by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants at 48 weeks with change in waist circumference ≥ 5 cm</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Waist circumference will be measured in standing position with a non-stretchable measuring tape and to the nearest 0.1 centimeter (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants at 48 weeks with change in Body weight ≥ 10%</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Body weight will be measured in kilograms (kg) to the nearest 0.1 kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants at 48 weeks with change in Fat mass ≥ 5% ≥ 10% ≥ 15%</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess the change in fat mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants at 48 weeks with change in Fat mass ≥ 10% with &lt;5% decrease (or increase) in lean mass</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of weight loss due to fat mass or lean mass at 48 weeks by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline at 48 weeks in fat mass (kg) by bioelectrical impedance analysis (BIA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition. An estimate of total body water (TBW) is derived by measuring electrical impedance of body tissues, from which fat-free mass (FFM) and body fat (adiposity) are estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at 48 weeks in fat mass (kg) by bioelectrical impedance analysis (BIA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition. An estimate of total body water (TBW) is derived by measuring electrical impedance of body tissues, from which fat-free mass (FFM) and body fat (adiposity) are estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline at 48 weeks in lean mass (kg) by bioelectrical impedance analysis (BIA)</measure>
    <time_frame>At baseline 48 weeks</time_frame>
    <description>Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition and will be used to assess lean mass (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline at 48 weeks in lean mass (kg) by dual-energy x-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline 48 weeks in lean mass (percent lean mass) by bioelectrical impedance analysis (BIA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Bioelectrical impedance analysis (BIA) is a widely used method for estimating body composition and will be used to assess percent change in lean mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline 48 weeks in lean mass (percent lean mass) by dual energy X-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Dual energy X-ray absorptiometry (DXA) will be used to assess changes in body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability measurements throughout 48 weeks by TEAEs</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Incidence and severity of treatment emergent adverse events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with change from baseline in BMI categories at 48 weeks</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>BMI categories:&#xD;
i. Healthy weight: 18.5 kg/m2 to 24.9 kg/m2 ii. Overweight: 25 kg/m2 to 29.9 kg/m2 iii. Obesity class 1: 30 kg/m2 to 34.9 kg/m2 iv. Obesity class II: 35 kg/m2 to 34.9 kg/m2 v. Obesity class III: ≥ 40 kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with change from baseline in WHtR ratio categories at 48 weeks</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>WHtR ratio categories: &lt;0.5; 0.5-0.59; ≥0.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment effects on glucose metabolism in HbA1c</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Change from baseline in HbA1c (mmol/mol) at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment effects on self-reported health status quality of life</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>Change from baseline at 48 weeks in Quality of Life Short Form 36 (SF-36) survey. To assess a subject's overall health related quality of life, as well as the physical functioning score. SF- 36 scores range from 0 (worst) to 100 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment effects on self-reported weight-related quality of life</measure>
    <time_frame>At baseline and 48 weeks</time_frame>
    <description>The Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQOL-Lite CT) is a 20-item modified survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day- to-day life, as well as the physical functioning score. Scores range from 0 (worst) to 100 (best)</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">690</enrollment>
  <condition>Obesity</condition>
  <condition>Obese</condition>
  <condition>Overweight or Obesity</condition>
  <arm_group>
    <arm_group_label>Bimagrumab placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimagrumab placebo + 1.0 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimagrumab placebo + 2.4 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive i.v. bimagrumab placebo at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg bimagrumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 10 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28 and 40, and 2.4 mg s.c. semaglutide weekly per the dose escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/kg bimagrumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16. 28, and 40, and 1.0 mg s.c. semaglutide weekly per the dose escalation schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 30 mg/kg i.v. bimagrumab at baseline, and at Weeks 4, 16, 28 and 40, and 2.4 mg s.c. semaglutide per the dose escalation schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bimagrumab</intervention_name>
    <description>Human monoclonal antibody to the activin receptor type II</description>
    <arm_group_label>10 mg/kg bimagrumab</arm_group_label>
    <arm_group_label>10 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>10 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
    <arm_group_label>30 mg/kg bimagrumab</arm_group_label>
    <arm_group_label>30 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>30 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Glucagon-like peptide-1 (GLP-1) receptor agonist</description>
    <arm_group_label>10 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>10 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
    <arm_group_label>30 mg/kg bimagrumab + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>30 mg/kg bimagrumab + 2.4 mg semaglutide</arm_group_label>
    <arm_group_label>Bimagrumab placebo + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>Bimagrumab placebo + 2.4 mg semaglutide</arm_group_label>
    <other_name>Wegovy</other_name>
    <other_name>Ozempic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bimagrumab Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Bimagrumab placebo</arm_group_label>
    <arm_group_label>Bimagrumab placebo + 1.0 mg semaglutide</arm_group_label>
    <arm_group_label>Bimagrumab placebo + 2.4 mg semaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  A written informed consent must be obtained before any study-related assessments are&#xD;
             performed.&#xD;
&#xD;
          -  Men and women between 18 and 80 years, inclusive; women of child-bearing potential&#xD;
             (defined as those who are not post-menopausal or post-surgical sterilization) must&#xD;
             meet both of the following criteria:&#xD;
&#xD;
               -  Two negative pregnancy tests (at screening and at randomization, prior to dosing)&#xD;
&#xD;
               -  Use of intrauterine device, from at least 3 months before the baseline visit&#xD;
                  through at least 4 months after the last dose of bimagrumab/placebo i.v., and an&#xD;
                  additional contraceptive (barrier) method from screening through at least 4&#xD;
                  months after the last dose of bimagrumab/placebo i.v.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated&#xD;
             comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)&#xD;
&#xD;
          -  Stable body weight (± 5 kg) within 90 days of screening, and body weight &lt;150 kg&#xD;
&#xD;
          -  Have a history of at least one self-reported unsuccessful behavioral effort to lose&#xD;
             body weight&#xD;
&#xD;
          -  Able to communicate well with the Investigator, comply with the study requirements and&#xD;
             adhere to the diet and activity programs for the study duration&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of, or known hypersensitivity to, monoclonal antibody drugs or a&#xD;
             contraindication to semaglutide (Ozempic® or Wegovy®)&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment or within 30 days or 5&#xD;
             half-lives of enrollment, whichever is longer, or longer if required by local&#xD;
             regulations&#xD;
&#xD;
          -  Treatment with any medication for the indication of obesity within the past 30 days&#xD;
             before screening&#xD;
&#xD;
          -  Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5%&#xD;
             Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic&#xD;
             drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired&#xD;
             glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet&#xD;
             and exercise) is not an exclusion.&#xD;
&#xD;
          -  Any chronic infections likely to interfere with study conduct or interpretation such&#xD;
             as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV).&#xD;
             History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active&#xD;
             COVID-19 infection.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or&#xD;
             longer if required by local regulation, or plasma donation (&gt; 250 mL) within 14 days&#xD;
             prior to the first dose&#xD;
&#xD;
          -  Any disorder, unwillingness, or inability not covered by any of the other exclusion&#xD;
             criteria, which in the Investigator's opinion, might jeopardize the subject's safety&#xD;
             or compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Attie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Versanis Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Brookvale</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Camberwell</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Heidelberg Heights</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Morayfield</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Saint Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Sippy Downs</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Southport</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Nelson</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versanis Investigational Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>October 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bimagrumab</keyword>
  <keyword>semaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

